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are related to each other may result in erroneous
interpretation of data.
One of the most common errors made by
biological scientists, whose main focus and
education are not in the area of pharmacokinetics, is
the distinction between mathematical and
physiological relationships among PK parameters
(2). In other words, when two PK parameters are
changed, which parameter is the cause and which
one is the effect. For example, a recent heated
discussion was erupted among some of the
subscribers to the PharmPK LISTSERV† about
whether the clearance of a drug is dependent on the
rate of elimination or vice versa, with apparently no
final resolution. The advocates of the dependency
of CL on the rate of elimination (dAe/dt) cited the
following equation as evidence:
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Abstract Pharmacokinetic (PK) software packages
are widely used by scientists in different disciplines
to estimate PK parameters. However, their use
without a clear understanding of physiological
parameters affecting the PK parameters and how
different PK parameters are related to each other
may result in erroneous interpretation of data.
Often, mathematical relationships used for the
estimation of PK parameters obscure the true
physiological relationships among these parameters,
prompting a discussion of which parameter came
first and giving the appearance of the-chicken-andthe-egg dilemma. In this article, the author attempts
to show how different PK parameters are related to
physiological parameters and each other by using
various scenarios and examples. In particular, the
relationship between clearance and the rate of
elimination and that among the other major PK
parameters are explored. It is concluded that there is
no dilemma in interdependency of the PK
parameters, and the relationships among the PK
parameters and between PK and physiological
parameters are clear.

CL =

dAe /dt
C

(1)

The argument is that because in practice, CL is
sometimes determined from the rate of elimination,
it is obvious that the latter influences the former.
The proponents of the dependency of the rate of
elimination to CL, on the other hand, state that the
correct physiological presentation of the above
equation is:

dAe /dt = CL × C

(2)

with a definition of CL as the proportionality
constant relating the rate of elimination to the blood
concentration. This group argues that although in
practice CL may be estimated using Equation 1, it is
the rate of elimination that is dependent on CL, not
vice versa.
This may seem a matter of semantics or give
the impression of the-chicken-and-the egg dilemma.
However, neither is true because there is indeed a
clear physiologic cause and effect relationships
among PK parameters, including clearance and rate
of elimination, as demonstrated in the following
sections.
It should be noted that the concepts presented
here are not new and have been known by
pharmacokineticists for many years. However, the
aim of this presentation is to highlight the
interdependence of PK parameters in an integrated
and focused manner with some examples.

INTRODUCTION
The origin of pharmacokinetics is attributed to an
article written by Torsten Torell in 1937 (1). After
an
initial
fascination
with
mathematical
relationships defining this discipline, came the
introduction of a large number of easy-to-use
pharmacokinetic (PK) software packages. Because
of widespread application of pharmacokinetics in
other disciplines, such as biology, pharmacology,
and physiology, and the availability of software, the
use of pharmacokinetics in biological sciences has
grown substantially in the last two decades.
However, the use of the PK software without a clear
understanding of physiological parameters affecting
the PK parameters and how different PK parameters
Corresponding Author: Reza Mehvar, Ph.D., School of
Pharmacy, Texas Tech University Health Sciences Center, 1300
Coulter, Amarillo, TX 79106. reza.mehvar@ttuhsc.edu.

† A Listserv maintained by Dr. David Bourne at the University of
Oklahoma (http://www.boomer.org/pkin/). The message thread
was “Clearance and Elimination.”
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values. For these drugs, CLint decreases with an
increase in the blood concentrations. For simplicity,
we shall assume that our drug is metabolized by a
single enzyme with a VMAX of 1.5 mg/min and a KM
of 0.1 mg/L. Further, its therapeutic concentration
ranges from 1 to 10 µg/L and its free fraction in
blood (fub) is 0.1. This means that at therapeutic
concentrations, the free drug concentrations (Cu)
(0.1-1 µg/L) are much lower than KM (0.1 mg/L).
Therefore, linear metabolism is expected within this
range as CLint stays close to 15 L/min:

THE RELATIONSHIP BETWEEN CLEARANCE
AND RATE OF ELIMINATION
For illustration purposes, we shall select a
hypothetical drug with elimination through hepatic
metabolism only, although the same principles are
valid for drugs with exclusive renal elimination or a
combination of renal and hepatic elimination.
Figure 1 demonstrates the cellular events in the
liver that lead to the metabolism of drugs.

Blood
Unbound
Drug (CU)

fub

CLint ≈

Bound
Drug

Q

CLint

CLint =

Metabolite

VMAX
KM+CU

Figure 1: Factors affecting the metabolism of a
hypothetical drug by the liver enzymes.

Scenario 1: the basics
The metabolism of our hypothetical drug during
one pass through the liver is depicted in Fig. 2.

The intrinsic capability of the liver enzymes in the
hepatocytes to metabolize the drug (CLint) is
dependent on the Michaelis-Menten constants, VMAX
(maximum rate of metabolism) and KM (drug
concentration producing half of VMAX), and drug
concentration at the site of metabolism (Cu) as
defined by the following equation:

CLint =

VMAX
K M + Cu

Portal Vein/
Hepatic Artery

Hepatic Vein

Liver
Cout: 3 µg/L

Q: 1.5 L/min
Cin: 6 µg/L

(3)

Metabolite

For
majority
of
drugs,
therapeutic
concentrations result in Cu values much lower than
KM, hence for these drugs CLint becomes a constant
independent of the blood concentrations within the
therapeutic range:

V
CLint ≈ MAX
KM

(5)

It should be noted that this parameter (CLint) is
the intrinsic capability of the liver to remove the
drug in the absence of any supply (liver blood flow)
limitation. However, as demonstrated in Fig. 1, the
access of the liver enzymes to the drug is limited by
other parameters such as the liver blood flow (Q),
free fraction of the drug in the blood (fub), and
permeability of the hepatocytes to the drug.
However, in most cases, permeability of the
hepatocytes to the drug is not the rate-limiting step
in the metabolism of most drugs.
In the following sections, we will look at the
metabolism of this hypothetical drug at a macro
level by presenting three different scenarios.

Hepatocyte
Unbound
Drug (CU)

1.5 mg/min
≈ 15 L/min
0.1 mg/L

Figure 2: The metabolism of a hypothetical drug in one
single pass through the liver based on Scenario 1 (see
text for details).

For demonstration purposes, we assume that the
concentrations of the drug entering and leaving the
liver are 6 and 3 µg/L, respectively. This indicates
that 50% of the drug entering the liver is converted
to a metabolite or, in other words, the fraction of the
drug extracted by one single-pass through the liver

(4)

This is not true for drugs such as phenytoin
where therapeutic concentrations are close to the KM
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(extraction ratio, E) is 0.5. As demonstrated in Fig.
1, assuming high permeability, the extraction ratio
(E) is dependent on Q, fub, and CLint. Several models
have been proposed (3-5) to define the relationship
between E and its three determinants. One of the
widely-used models is the well-stirred or venous
equilibrium model, which defines this relationship
using the following equation (3):

E≈

f ub ⋅ CLint
0.1 × 15
=
= 0.5
Q + f ub ⋅ CLint 1.5 + (0.1 × 15)

Scenario 2: a change in the blood concentration
Let us assume that the drug concentration entering
the liver is now changed from 6 µg/L to 4 µg/L
(Fig. 3). Because of the linear metabolism of the
drug, the change in Cin is not expected to affect
CLint, Q, or fub of the drug. Therefore, as Equation 6
suggests, the E of the drug (0.5) does not change.
Consequently, the outlet concentration will be 2
µg/L in this case (Fig. 3). The CL of the drug,
defined as the volume of blood cleared of drug per
unit of time, also remains the same as that in
Scenario 1 (0.75 L/min, Fig. 3). This is also
consistent with the calculation of CL based on
Equation 7 or 8, as none of the determinants of CL
were changed. However, the rate of elimination of
the drug in this case (1.5 L/min x 2 µg/L or 3
µg/min) will be lower than that in Scenario 1 (1.5
L/min x 3 µg/L or 4.5 µg/min). Again, the rate of
elimination may also be estimated using Equation
2:

(6)

Considering that the blood leaving the liver
contains a concentration half of that entering the
liver (Cin) (Fig. 2), one may state that half of the
blood is totally cleared of the drug and the other
half has the same concentration as Cin. In other
words, half of the blood is cleared of the drug per
unit of time. This is one of the definitions of
clearance, which in this case is equivalent to 0.75
L/min (0.5 x 1.5 L/min), forming the basis of the
following equation:

CL = Q × E

Portal Vein/
Hepatic Artery

Liver

(7)

Equations 6 and 7 clearly indicate both E and
CL are dependent on fub, CLint, and Q. Substituting
Equation 4 and 6 into 7 would clearly show the
determinants of CL for a drug with linear
metabolism:

VMAX
KM
CL = Q ⋅
V
Q + f ub ⋅ MAX
KM

Hepatic Vein

Cout: 2 µg/L

Q: 1.5 L/min
Cin: 4 µg/L

Metabolite
Figure 3: The metabolism of a hypothetical drug in one
single pass through the liver based on Scenario 2 (a
decrease in the inlet drug concentration; see text for
details).

f ub ⋅

(8)

dAe/dt = CL × C = 0.75 L/min × 4 μg/L = 3.0 μg/min

Any change in Q, fub, VMAX, and/or KM may
potentially affect the CL of the drug. The degree of
dependency of CL on any of these parameters,
however, is influenced by the initial values of these
parameters relative to each other, and its discussion
is outside the scope of this communication.
Now that we have dealt with CL, let us consider
the rate of elimination in our example (Fig. 2).
Considering a Q of 1.5 L/min and the inlet and
outlet concentrations of 6 and 3 µg/L, respectively,
this means that the rate of elimination (metabolism)
of the drug is 4.5 µg/min (1.5 L/min x 3 µg/L). The
same value may also be obtained using Equation 2:

This observation indicates that the rate of
elimination is dependent on the blood concentration
of the drug, whereas CL is independent of blood
concentration
for
a
drug
with
linear
pharmacokinetics.
Scenario 3: a change in the clearance
For this scenario, we shall change the CL of the
drug and keep the inlet concentration the same as
that in Scenario 1. Based on Equation 7, CL is
dependent on Q and E. Additionally, E is dependent
on Q, fub, and CLint (Equation 6), with the latter
being dependent on VMAX and KM (Equation 4). A
change in any of the determinants of CL, which are
Q, fub, VMAX and KM (Equation 8), can potentially
alter CL. Let us assume that the VMAX of the drug is
increased by a factor of 2 from 1.5 mg/min to 3

dAe/dt = CL × C = 0.75 L/min× 6 μg/L = 4.5 μg/min
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the rate of elimination.
2. When the blood concentration is kept constant
and one of the determinants of CL is changed,
the change in CL is proportionally reflected in a
change in the rate of elimination, indicating the
dependency of the rate of elimination on the CL
and its determinants (Scenario 3).
3. Consequently, the rate of elimination is
dependent on both the CL and blood
concentration of the drug. Although CL is not
affected by the rate of elimination, it is
dependent on its determinants CLint, fub, and Q.
Coming back to the-chicken-and-the-egg dilemma,
it is clear that there is no dilemma regarding the rate
of elimination and CL; it is the rate of elimination
that is dependent on CL and not vice versa.
Therefore, although both Equations 1 and 2 are
mathematically correct, only Equation 2 is
physiologically valid. Researchers often use
Equation 1 to estimate CL. However, it should not
be forgotten that it is CL that determines the rate of
elimination.

mg/min as a result of an interacting drug. This in
turn results in a two-fold increase in CLint from 15
L/min to 30 L/min:

CLint ≈

VMAX 3.0
≈
= 30 L/min
KM
0.1

The increased CLint will cause an increase in E
and CL as demonstrated in Figure 4 and by
Equations 6 and 7:

E≈

f ub ⋅ CLint
0.1 × 30
=
= 0.67
Q + f ub ⋅ CLint 1.5 + (0.1 × 30)

CL = 1.5 × 0.67 = 1.0 L/min
Portal Vein/
Hepatic Artery

Hepatic Vein

Liver
Cout: 2 µg/L

Q: 1.5 L/min
Cin: 6 µg/L

THE RELATIONSHIPS AMONG OTHER
PHARMACOKINETIC PARAMETERS

Metabolite

As the above discussion suggests, CL is a major PK
parameter that is related to the efficiency of the
eliminating organs, such as the liver and kidneys, to
remove the drug from the body. Another major PK
parameter, which is at the same level of importance
as CL, is the volume of distribution (V), which is an
indication of the extent of the distribution of the
drug within the body. Similar to CL, V is
determined by the physiological parameters of the
patient and the physicochemical characteristics of
the drug. The volume of distribution of drugs at
steady state (VSS) is dependent on the volumes of
blood (VB) and tissue (VT) and free fractions of the
drug in blood (fub) and tissues (fut) according to the
following equation (6):

Figure 4: The metabolism of a hypothetical drug in one
single pass through the liver based on Scenario 3 (an
increase in the clearance; see text for details).

Figure 4 also clearly shows that the rate of
elimination of the drug in this case is 6 µg/min (1.5
L/min x 4 µg/mL). As in the previous scenarios, the
rate of elimination can also be calculated using
Equation 2:

dAe /dt = CL × C = 1.0 L/min × 6 μg/L = 6.0 μg/min
This scenario shows that when CL is changed, the
rate of elimination of the drug changes
proportionally.
Summary of scenarios
The three scenarios discussed above for a drug with
linear pharmacokinetics suggest the following
conclusions:
1. When the blood concentration of the drug
changes, CL remains unchanged, whereas the
rate of elimination of the drug changes
proportionally. In other words, the change in
the rate of elimination does not affect CL
(Scenario 2). This shows the dependency of the
rate of elimination to the blood concentration.
Further, it shows the independence of CL from

VSS = VB +

f ub
VT
f ut

(9)

Both V and CL are independent parameters,
meaning that a change in one does not necessarily
result in a change in the other parameter, although
there may be situations when a change in an
underlying physiologic factor would affect both
parameters (such as a change in fub).
A third major PK parameter is the elimination
half life (t1/2) or rate constant (k). However, it
should be noted that, in contrast to CL and V, t1/2 or
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k does not represent any single physiological
process. Instead, it is a composite parameter,
reflecting both CL and V processes (2). Therefore,
although these three major parameters are
mathematically related to each other, one should be
aware that t1/2 or k is dependent on both CL and V
and not vice versa. Therefore, although one may
use the mathematical relationship presented in
Equation 10 to estimate CL, one should be aware
that the proper equations describing the
interdependency of these three parameters are
presented by Equations 11 and 12:

CL = k ⋅ V
k=

CONCLUSIONS
The arguments presented here are summarized in
Figure 5 in terms of hierarchy of the major
pharmacokinetic parameters (constants) and their
interdependence. Furthermore, the effects of these
kinetic parameters on the blood concentrations and
elimination rate after a single intravenous dose are
demonstrated.
Although the hypothetical drug used here only
underwent hepatic metabolism, the principles
discussed here are equally applicable for drugs
undergoing renal and/or hepatic elimination. When
different organ clearances are involved in the drug
elimination, the total CL will be a summation of the
individual clearances. This, however, does not
change the dependency of the rate of elimination on
total CL.

(10)

CL
V

t1/ 2 =

This issue has been discussed in detail in a
recent article (2), hence will not be covered in more
detail here.

(11)

0.693V
CL

(12)

PK Constants
Level 1

Level 2

VMAX

Q

Dose

Level 4
Rate of Elimination
160
140

dAe
= CL ⋅ C
dt

120

CLint
KM

Level 3

PK Variables

100

CL

80
60
40
20
0

fub

t1/2

fut
VT

0

Time
20

40

Time

Blood Conc.
160
140

CL

C=

120

V

100
80

Dose − V
⋅e
V

⋅t

Single
IV
Bolus
Dose

60
40
20
0
0

VB

Time

20
Time

40

Figure 5: The relationship among physiological and PK parameters for a hypothetical drug eliminated only by hepatic
metabolism after administration of a single intravenous bolus dose.
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ABBREVIATION LIST
C
Cu
Cin
Cout
CL
CLint
dAe/dt
E
fub
fut
k
KM
Q
t1/2
V
VB
VMAX
VSS
VT

Blood Concentration
Unbound Concentration
Inlet Concentration
Outlet Concentration
Clearance
Intrinsic Clearance
Rate of Elimination
Hepatic Extraction Ratio
Drug Unbound Fraction in Blood
Drug Unbound Fraction in Tissue
Elimination Rate Constant
Michaelis-Menten Constant
Hepatic Blood Flow
Elimination Half Life
Volume of Distribution
Blood Volume
Maximum Rate of Metabolism
Volume of Distribution at Steady State
Tissue Volume
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